Chris has been involved in the research, medical device and biotechnology industry for more than 25 years. Chris was a co-founder of Cytori Therapeutics, Inc./Macropore Biosurgery, Inc. and was CEO/Vice-Chairman of the Board (1996-2014). During his tenure, he brought in more than $400 million and completed transactions with leading device and pharmaceutical companies including GE Healthcare, Olympus Medical, Medtronic, Astellas Pharma, Senko Medical, Kensey Nash, Green Hospital Supply, Lorem Vascular and Mast Biosurgery as well as established a $106 million development contract with BARDA.
Chris is an inventor on 96 medical product patent applications. He has presented in more than 100 regenerative medicine, technology and financial conferences and has been an invited lecturer in entrepreneurship and biotechnology at both the Anderson School of Management at UCLA and Rady’s School of Management at UCSD. Chris has a BA from the University of California at San Diego in Economics and an MBA from the University of Phoenix.
Interview questions:
Introduction: Please provide an introduction to Paracrine Cell Therapy and what has been accomplished so far.
Business Model: Can you explain your business model and products?
Technology: So these cells come from the fat tissue – Why Fat?
3 in 1 Therapy: What are the mechanisms of action of Paracrine Cell Therapy?
One & Done: How many times do patients need to be treated?
Clinical Trials: What are the clinical trials that Paracrine is focused on?
Capital: What are your plans for fundraising?
Connect with Chris on LinkedIn
PARACRINE is a biopharmaceutical company focused on late-stage IDE clinical trials for the world’s first autologous, device-based cell therapy. We are targeting some of the greatest unmet needs in healthcare including heart failure, diabetic foot ulcers as well as a rare condition in hand dysfunction related to scleroderma. Uniquely, our heterogeneous cell population produces a 3-in-1 therapy that includes vascular therapy, immunotherapy, and regenerative therapy that we believe is a game changer for complex conditions. Simply put, PARACRINE Cell Therapy amplifies the body’s innate ability to heal itself.
Recent articles:
Paracrine aims to use its autologous cell therapy platform to treat a variety of unmet needs
Edwin Warfield, CEO of citybiz.co, conducts CEO Interviews.
If you’re interested in a citybiz CEO Interview, please contact
Edwin Warfield – edwin.warfield@citybizlist.com
